Compare Heron Therapeutics Inc (HRTX) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs ProShares UltraPro QQQ ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while ProShares UltraPro QQQ ETF trades at $70.17. The key difference: ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | TQQQ | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.96 | $87.22 |
52-Week Low | $0.39 | $37.89 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
TQQQ trades at $67.65, up 0.18% on the day, with a bearish technical signal driven by moving averages. The ETF faces structural costs and volatility risks, as highlighted in recent news. Key support lies at $66, with resistance at $69. Recent articles emphasize the amplified downside potential during market selloffs, questioning the long-term viability of leveraged strategies.
Outlook remains cautious due to high volatility and compounding costs. Opportunities exist for tactical traders during uptrends, but risks include severe drawdowns and daily rebalancing effects. Investors should weigh the 3x leverage against potential wealth destruction in downturns, as seen in 2022's 81% drop versus Nasdaq's 33% decline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
